関連する実験動画

Updated: Sep 10, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

単細胞レベルでの子宮内膜がん分子亜型におけるPI3K経路遺伝子変異の進化と同時発生

Arnaud Da Cruz Paula¹, Yingjie Zhu², David N Brown³

¹i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Porto, Portugal.

Clinical cancer research : an official journal of the American Association for Cancer Research

|August 20, 2025

まとめ

エンドメトリオイド子宮内膜がん (EECs) は,PI3K経路の異なった変異の進化を示しています. NSMP EECは線形に進化し,MMRd/POLE EECは収束する進化を示し,潜在的な治療に影響を及ぼします.

科学分野:

腫瘍学
ゲノミクス
分子生物学

背景:

PI3K経路は,子宮内膜がん (EEC) で頻繁に変化し,しばしば複数の突然変異が同時発生します.
単剤PI3K阻害剤による治療の成功が限られていることは,複雑な進化的メカニズムを示唆している.

研究の目的:

EEC の異なる分子サブタイプで同時に発生する PTEN,PIK3CA,PIK3R1 変異の進化軌道を調査する.
単細胞配列解析を用いて,これらの変異が線形または収束進化によって発生するかどうかを決定する.

主な方法:

特定の分子プロファイル (NSMP),不一致修復欠陥 (MMRd),およびPOLEサブタイプを超えて,バンクされたEECから50009の細胞の単核DNAシーケンシング.
PTEN,PIK3CA,PIK3R1のホットスポット変異を含む64の癌に関連する遺伝子の標的配列決定.
EECの細胞系と非悪性サンプルを使って誤差率と偽陽性のフィルタリングを行いました

主要な成果:

NSMP EECは線形進化を示し,PI3K経路の変異はほぼすべての細胞に影響した.
MMRd EECは,細胞の3. 9%から96%に突然変異を呈した.
POLE EECは最も高いクローン多様性を示し,複数の小型のサブクローンが収束して進化した.

結論:

PI3K経路の変化は,NSMP EECと比較してMMRd/POLE EECで顕著に進化する.
これらの独特な進化パターンは重要な治療的意味を持つかもしれません
PI3K経路のシグナル伝達とサブクローナル変異を有するEECにおける阻害反応に関するさらなる研究が必要である.

さらに関連する動画

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

関連する概念動画

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...